Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)

The company who produce pembrolizumab, Merck Sharp & Dohme, have requested a suspension of the submission until after CHMP opinion is received. NICE has considered this request and has agreed to suspend the appraisal. Therefore, the evidence submission deadline (5pm on 28 February 2018) has also been suspended and the committee meeting on 12 June 2018 has been cancelled. We will provide a further update on the scheduling of this appraisal in due course.